Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
No open-market purchases or sales by Processa Pharmaceuticals, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Processa Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 22 | 19 | −3 |
| Shares | 1.65M | 1.39M | −260.6K (−15.8%) |
| Value | $852.6K | $691.4K | −$161.1K (−18.9%) |
New holders (3)
Institutions that held Processa Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 282,837 | $140.7K | 0.00% |
| Susquehanna International Group, LLP | 28,108 | $14.0K | 0.00% |
| Royal Bank of Canada | 151 | $0 | 0.00% |
Sold out (6)
Institutions that held Processa Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 48,951 | $24.5K |
| Janney Montgomery Scott LLC | 46,231 | $23.0K |
| UBS Group AG | 22,459 | $11.2K |
| Jane Street Group, LLC | 10,040 | $5.02K |
| WealthPLAN Partners, LLC | 1,000 | $500 |
| Farther Finance Advisors, LLC | 487 | $244 |